Group 1 - The company has clarified that its anti-hair loss foam product, KX-826, is part of its KOSHINÉ cosmetics brand and that the sales target of RMB 100 million is a long-term goal rather than a short-term sales expectation [1] - The cosmetics sales business is currently small and auxiliary compared to the company's core business of drug development and commercialization [1] - As of the announcement date, the company has 121 employees, with 69 dedicated to drug research and supply, and 24 focused on cosmetics sales and marketing [1] Group 2 - The board has confirmed that the cash flow from the cosmetics business will be used to fund medical and biological applications and development [2] - The company is actively negotiating bank financing expected to be granted in the first quarter of 2026 and is also seeking equity financing from potential investors [2] - The board believes that the company's financial resources and liquidity are sufficient to support its operations, research, and commercialization of core products [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部份內容而產生或因 倚賴該等內容而引致的任何損失承擔任何責任。 開 拓 藥 業 有 限 公 司 * KINTOR PHARMACEUTICAL LIMITED （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股 份 代 號：9939） 有關自願公告的補充公告 茲提述日期為2026年1月21日的自願公告（「該公告」）。除文義另有所指外，本 公告所用詞彙與該公告所界定者具有相同涵義。 董事會謹此提供進一步資料說明，防脫泡沫劑產品（「該產品」）為本公司化妝 品品牌KOSHINÉ旗下以KX-826為主要成分的產品之一。本公司謹此澄清，儘 管銷售代理協議為進一步推動本公司化妝品商業化提供了有利機會，但與本 集團的上市業務（即本公司核心產品KX-826及GT20029及其他管線產品的開發 及商業化）（「上市業務」）相比，該化妝品銷售業務目前規模較小，屬輔助性質。 謹此說明，該公告所披露的人民幣100百萬元銷售目標是按累計基準計量的長 期目標，而非預期於短期內達致 ...

Group 1 - The core point of the article is that Suzhou Kaituo Pharmaceutical Co., Ltd. has obtained a patent for a compound related to thioethylurea, indicating its ongoing innovation in the pharmaceutical sector [1] - The patent, titled "An Intermediate for Thioethylurea Drugs and Its Preparation Method and Use," was granted with the announcement number CN116829554B, and the application date was January 2022 [1] - Suzhou Kaituo Pharmaceutical was established in 2009 and is primarily engaged in research and experimental development, with a registered capital of 87.057437 million RMB [1] Group 2 - The company has made investments in four enterprises and has participated in 11 bidding projects [1] - Suzhou Kaituo Pharmaceutical holds 42 trademark registrations and 44 patent registrations, along with 31 administrative licenses [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2026年1月31日 | 狀態: | 新提交 | | --- | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | | 公司名稱: | 開拓藥業有限公司 | | | | 呈交日期: | 2026年2月2日 | | | I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09939 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 700,000,000 | USD | | 0.0001 | USD | | 70,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 70 ...

Core Viewpoint - The company, 开拓药业-B, announced a share buyback by its chairman, Dr. Tong Youzhi, indicating confidence in the company's future and potential for further investment after a quiet period [2][5]. Group 1: Share Buyback Details - Dr. Tong Youzhi plans to buy back approximately 4.7 million shares, representing about 0.9425% of the total issued share capital, at an average price of HKD 2.30 per share, with a total investment of around HKD 10.82 million [2][5]. - The buyback will occur from November 17, 2025, to January 23, 2026, and the price range for the shares will be between HKD 1.89 and HKD 2.81 [2][5]. Group 2: Market Reaction - Following the announcement, the stock price of 开拓药业-B increased by 3.43%, reaching HKD 3.02, with a trading volume of HKD 12.9761 million [2][5]. Group 3: Future Outlook - Dr. Tong expressed confidence in the overall development prospects and commercialization transformation of the company, suggesting potential for further share purchases after the quiet period ending on March 26, 2026 [2][5].

Group 1 - The stock of Akeso Inc. (09939.HK) increased by over 3% during trading, reaching a price of 3.01 HKD [2] - The trading volume amounted to 8.0533 million HKD at the time of reporting [2]

Core Viewpoint - The stock of Innovent Biologics-B (09939) has seen an increase of over 3%, currently trading at 3.01 HKD with a transaction volume of 8.0533 million HKD, following an announcement regarding share buyback by the company's chairman, Dr. Hui Zhi Tong [1] Group 1 - On January 26, Innovent Biologics-B announced that its board received notification from Dr. Hui Zhi Tong, the chairman, executive director, and CEO, regarding a share buyback plan [1] - Dr. Hui plans to acquire approximately 10.82 million HKD worth of shares through his wholly-owned company, KT International Investment Limited, in the open market, at an average price of 2.30 HKD per share, with a price range of 1.89 HKD to 2.81 HKD [1] - The buyback will involve 4.7 million shares, representing about 0.9425% of the total issued share capital as of the announcement date [1] Group 2 - Dr. Hui expressed confidence in the overall development prospects and commercialization transformation of the company [1] - He does not rule out the possibility of further increasing his stake in the company after the silent period, which ends on March 26, 2026 [1]

Group 1 - On January 26, 2023, Keda Pharmaceuticals disclosed that its chairman, Zhongyou Zhi, invested HKD 10.82 million to increase his stake by 4.7 million shares [1][2] - A total of nine listed companies announced plans to reduce their holdings, including Kaipu Detection, Ruike Laser, Inspur Information, Yashichuangneng, Chaoda Equipment, Jianlong Micro-Nano, Sun Cable, Jianghang Equipment, and Shengda Bio [1][2] Group 2 - Kaipu Detection's shareholders plan to collectively reduce their holdings by no more than 3.2154% of shares [2] - Ruike Laser's directors and executives, including Wang Wei, intend to reduce their holdings by no more than 0.085% of shares [2] - Inspur Information's Huang Shipeng and executive Liu Jun plan to reduce their holdings by no more than 30,000 shares [2] - Yashichuangneng's controlling shareholder's concerted action party plans to passively reduce its stake by 3% [2] - Chaoda Equipment's shareholder, Zhongda Investment, intends to reduce its holdings by no more than 1.55% of shares [2] - Jianlong Micro-Nano's shareholder, Shen Yunlong, plans to reduce its holdings by no more than 2.00% of shares [2] - Sun Cable's shareholder, Qili Group, intends to reduce its holdings by no more than 3% of shares [2] - Jianghang Equipment's shareholder, Guoxin Capital, plans to reduce its holdings by no more than 1.00% of shares [2] - Zhidaniu's shareholder, Wanjian Investment, intends to reduce its holdings by no more than 3% of shares [2]

Company News - China Power (02380.HK) expects a total consolidated electricity sales volume of 10.73105 million MWh by December 2025, a decrease of 2.31% year-on-year; the total annual electricity sales volume is approximately 126 million MWh, down 1.27% year-on-year [2] - Harbin Electric (01133.HK) anticipates a net profit attributable to shareholders of approximately RMB 2.65 billion for the fiscal year 2025, compared to RMB 1.686 billion in the previous year, mainly due to increased operating revenue and improved product profitability [2] - Singularity Guofeng (01280.HK) has entered into a GPU distribution cooperation agreement with Muxi Co., aiming to enter the domestic AI computing power market [2] - Dongyang Sunshine Pharmaceutical (06887.HK) has signed a strategic cooperation agreement with Shenzhen Jingtai to establish a joint venture for building an AI-driven drug research and development platform [2] - Weisheng Pharmaceutical-B (02561.HK) has received approval from the National Medical Products Administration for the marketing authorization application of injectable Long Pei growth hormone [2] - Kintor Pharmaceutical-B (02171.HK) issued a profit warning, expecting a net loss for 2025 to be reduced to no more than approximately RMB 120 million [2] - Zhaoke Ophthalmology-B (06622.HK) is advancing the commercialization process of BRIMOCHOL PF for treating presbyopia in Singapore and Vietnam through partnerships with AFT and Qianshou [2] Additional Company Developments - Heng Rui Medicine (01276.HK) has received a clinical trial approval notice for SHR-1049 injection [3] - Baolong Real Estate (01238.HK) has had its bond restructuring plan approved by the relevant bondholders' meeting [3] Strategic Partnerships - Yabo Technology Holdings (08279.HK) has entered into a technical service agreement with Hong Kong Gold Exchange Limited [4] - Future Data Group (08229.HK) has signed a strategic cooperation framework agreement with Linghe Culture [4] - Howey Group (00501.HK) plans to invest up to USD 50 million to subscribe for shares in Aixin Yuanzhi's initial public offering [4] Buyback Activities - Xiaomi Group-W (01810.HK) repurchased 3.9872 million shares for HKD 140 million, with a repurchase price ranging from HKD 35.04 to HKD 35.22 [5] - China Metallurgical Group (01618.HK) repurchased 9.011 million shares for HKD 16.9299 million, with a repurchase price of HKD 1.87 to HKD 1.88 [5] - Geely Automobile (00175.HK) repurchased 4.401 million shares for HKD 72.952 million, with a repurchase price ranging from HKD 16.43 to HKD 16.65 [6] - Reshape Energy (02570.HK) completed the placement of a total of 4.536 million placement shares, raising approximately HKD 258 million [6] - Kintor Pharmaceutical-B (09939.HK) saw an increase of 4.7 million shares by Chairman Tong Youzhi [6]

Core Viewpoint - The company, 开拓药业-B (09939), announced that its chairman and CEO, Dr. Tong Youzhi, has increased his stake in the company by purchasing 4.7 million shares for approximately HKD 10.82 million, reflecting confidence in the company's future growth and commercialization potential [1]. Group 1: Share Purchase Details - Dr. Tong acquired the shares through his wholly-owned company, KT International Investment Limited, in the open market at an average price of HKD 2.30 per share, with a price range between HKD 1.89 and HKD 2.81 [1]. - This purchase represents approximately 0.9425% of the company's total issued share capital as of the announcement date [1]. Group 2: Management Confidence - Dr. Tong expressed strong confidence in the overall development prospects and commercialization transformation of the company [1]. - The board believes that this share purchase demonstrates Dr. Tong's firm belief in the clinical progress and growth potential of the company's innovative topical drugs, particularly in the hair loss treatment pipeline [1]. - The company maintains sufficient public float after this share purchase, indicating a stable shareholder structure [1].